Technical Updates, Quarterly Earnings, Legislated Requirements, Lawsuit Dismissal, and Revised Operational Structure - Research Reports on United Rentals, Lilly, Quest Diagnostics, Agilent and GE

NEW YORK, November 6, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding United Rentals, Inc. (NYSE: URI), Eli Lilly and Company (NYSE: LLY), Quest Diagnostics Inc. (NYSE: DGX), Agilent Technologies Inc. (NYSE: A) and General Electric Company (NYSE: GE). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7739-100free.

--
United Rentals, Inc. Research Reports
On November 3, 2014, the stock of United Rentals, Inc. (United Rentals) gained 1.59% to end the trading session at $111.81. During the session, the stock opened at $109.92, and fluctuated in the range of $109.90 - $113.61. A total of 1.66 million shares changed hands during the session. Moreover, the stock has gained 18.95% in the last six months, compared to the S&P 500 index which rose 7.27% during that period. Also, the stock closed above its 50-day and 200-day moving average of $110.06 and $100.32, respectively. The full research reports on United Rentals are available to download free of charge at:

http://www.analystsreview.com/Nov-06-2014/URI/report.pdf

--
Eli Lilly and Company Research Reports
On October 29, 2014, Eli Lilly and Company (Lilly) along with Boehringer Ingelheim announced that the Companies are changing the operational and financial structure of their diabetes alliance in certain countries. Under the revised agreement, 17 countries representing more than 90% of the alliance's anticipated market opportunity will continue their co-promotion work. Further, the duos will exclusively commercialize the respective molecules they brought to the alliance, in all other countries under revised financial terms that will include an upfront payment and ongoing payments paid to Lilly in lieu of commission payments in those markets. Lilly informed that the changes will be implemented starting January 1, 2015. The full research reports on Lilly are available to download free of charge at:

http://www.analystsreview.com/Nov-06-2014/LLY/report.pdf

--
Quest Diagnostics Inc. Research Reports
On October 23, 2014, Quest Diagnostics Inc. (Quest) announced its Q3 2014 financial results. Quest's net revenue in Q3 2014 increased 6.5% YoY to $1.9 billion. Diagnostic information services revenues increased 7.1% compared to the year ago quarter. Net income attributable to the Company, however, dropped to $129 million, or $0.88 per diluted share, from $405 million, or $2.68 per diluted share in the year ago period. Quest said that its Q3 2014 net income was negatively impacted by restructuring and integration costs associated with recent acquisitions and the company's ongoing efforts to drive operational excellence and simplify the organization. The Company said that its adjusted diluted EPS from continuing operations was $1.10 per diluted share in Q3 2014, up 7.8% YoY. Looking ahead, Quest now expects full-year 2014 revenue to grow approx. 3.5% YoY, versus previous growth guidance range of 2.5% to 3.5%. Also, full-year 2014 adjusted EPS guidance range was revised to $4.03 and $4.07, versus previous guidance of between $4.00 and $4.10. The full research reports on Quest Diagnostics are available to download free of charge at:

http://www.analystsreview.com/Nov-06-2014/DGX/report.pdf

--
Agilent Technologies Inc. Research Reports
On November 3, 2014, Agilent Technologies Inc. (Agilent) announced that patent infringement litigation claims against Agilent's microarray, Bioanalyzer and GeneSpring products have been dismissed by Genetic Technologies, Ltd (Genetic Technologies). According to Agilent, no settlement was involved and instead, both the Companies filed a mutual dismissal of all claims, in which Genetic Technologies dismissed its patent infringement claims and Agilent dismissed its counterclaims relating to non-infringement and invalidity. Victoria, Australia-based Genetic Technologies had accused Agilent and other life sciences companies of infringing a U.S. patent titled "Intron Sequence Analysis Method for Detection of Adjacent Locus Alleles as Haplotypes." In a same day separate release, Agilent also announced that it has completed the spinoff of its electronic measurement business, Keysight Technologies. Keysight started trading on NYSE under the symbol KEYS, with immediate effect. The full research reports on Agilent are available to download free of charge at:

http://www.analystsreview.com/Nov-06-2014/A/report.pdf

--
General Electric Company Research Reports
On November 4, 2014, General Electric Company's Digital Energy business announced that it is prepared to help U.K. utilities meet new government requirements mandating smart meters in every home by 2020. The Company said that its SGM1300 IEC smart electricity meter will provide utilities with the advanced metering infrastructure, while also helping customers get on-time, reliable and accurate billing information. Ed Myszka, General Manager, meters, GE's Digital Energy business, said, "The implementation of GE's SGM1300 smart meters across a utility's service network can provide a wide range of benefits for both the utility and its customers." The full research reports on General Electric are available to download free of charge at:

http://www.analystsreview.com/Nov-06-2014/GE/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review